These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31555705)

  • 1. The effects of citrate dialysate in hemodialysis on polymorphonuclear elastase interaction with tissue factor and its inhibitor.
    Li J; Sun S; Han M; Wang L; Liao R; Xiong Y; Li Y; Jiang H; Qin Z; Maharjan A; Cozzolino M; Zarbock A; Su B
    Ann Transl Med; 2019 Aug; 7(16):391. PubMed ID: 31555705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study.
    Naumnik B; Borawski J; Myśliwiec M
    Nephrol Dial Transplant; 2003 Jul; 18(7):1376-82. PubMed ID: 12808176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convulsions in hemodialysis (HD) patients with elevated polymorphonuclear leukocyte elastase (PMNE) levels.
    Nishimura T; Suga T; Takemura F; Nomoto Y; Sakai H
    Tokai J Exp Clin Med; 1997 May; 22(2):45-51. PubMed ID: 9608630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study.
    Naumnik B; Rydzewska-Rosołowska A; Myśliwiec M
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):480-6. PubMed ID: 20682597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis.
    Inoue A; Wada H; Takagi M; Yamamuro M; Mukai K; Nakasaki T; Shimura M; Hiyoyama K; Deguchi H; Gabazza EC; Mori Y; Nishikawa M; Deguchi K; Shiku H
    Clin Appl Thromb Hemost; 2000 Apr; 6(2):100-3. PubMed ID: 10775031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentrations of tissue factor and its inhibitor in chronic thromboembolic pulmonary hypertension: a step closer to explanation of the disease aetiology?
    Cisowska-Czajka ME; Mazij MP; Kotschy MH; Lewczuk J
    Kardiol Pol; 2016; 74(11):1332-1338. PubMed ID: 27221958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action.
    Hansen JB; Sandset PM; Huseby KR; Huseby NE; Bendz B; Ostergaard P; Nordøy A
    Br J Haematol; 1998 Jun; 101(4):638-46. PubMed ID: 9674734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis.
    Kario K; Matsuo T; Yamada T; Matsuo M
    Thromb Haemost; 1994 Mar; 71(3):275-9. PubMed ID: 8029788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum from hemodialysis patients inhibits basal and cytokine-stimulated tissue factor expression in vitro.
    Maderna P; Coleman P; Godson C; O'Meara YM; Brady HR
    J Am Soc Nephrol; 1999 Nov; 10(11):2403-6. PubMed ID: 10541301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration.
    Gori AM; Pepe G; Attanasio M; Falciani M; Abbate R; Prisco D; Fedi S; Giusti B; Brunelli T; Giusti B; Brunelli T; Comeglio P; Gensini GF; Neri Serneri GG
    Thromb Haemost; 1999 Apr; 81(4):589-93. PubMed ID: 10235445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Change of tissue factor pathway ratio during attack in patients with acute myocardial infarction and its clinical significance].
    Wang R; Wen BZ; Ma YT; Peng -; Li H; Zhong D; Li L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):198-202. PubMed ID: 19236778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms and plasma levels of tissue factor and tissue factor pathway inhibitor in venous thromboembolism.
    Kwon A; Jo SH; Jo YA; Park JY; Kim M; Kang HJ; Kim HS; Cho HC; Lee YK
    Blood Coagul Fibrinolysis; 2014 Jul; 25(5):416-21. PubMed ID: 24448154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue factor, its pathway inhibitor, and metabolic disturbances in long-term peritoneal dialysis.
    Zemanová P; Opatrný K; Opatrná S; Vít L; Sefrna F; Racek J
    Kidney Blood Press Res; 2003; 26(5-6):368-75. PubMed ID: 14610342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
    Falciani M; Gori AM; Fedi S; Chiarugi L; Simonetti I; Dabizzi RP; Prisco D; Pepe G; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue Factor, Tissue Factor Pathway Inhibitor and Factor VII Activity in Cardiovascular Complicated Type 2 Diabetes Mellitus.
    El-Hagracy RS; Kamal GM; Sabry IM; Saad AA; Abou El Ezz NF; Nasr HA
    Oman Med J; 2010 Jul; 25(3):173-8. PubMed ID: 22043333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina.
    Soejima H; Ogawa H; Yasue H; Kaikita K; Nishiyama K; Misumi K; Takazoe K; Miyao Y; Yoshimura M; Kugiyama K; Nakamura S; Tsuji I; Kumeda K
    Circulation; 1999 Jun; 99(22):2908-13. PubMed ID: 10359735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do the effects of a protease inhibitor, ulinastatin, on elastase release by blood transfusion depend on interleukin 6?
    Nishiyama T; Hanaoka K
    Crit Care Med; 2001 Nov; 29(11):2106-10. PubMed ID: 11700404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction].
    Xiong SL; Wang Q; Zheng L; Li JL; Wen ZB; He SL
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec; 27(12):1821-3. PubMed ID: 18158992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in polymorphonuclear leukocyte elastase concentrations and hemolysis parameters in patients transfused with different blood preparations, and in the blood preparations themselves.
    Nishiyama T
    J Anesth; 2008; 22(2):117-24. PubMed ID: 18500607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of tissue factor pathway inhibitor-1 on no-reflow in a rabbit model].
    Luo JG; Chen YD; Tian F; Wang CH; Lü Y; Yang XX; Lü SZ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Dec; 37(12):1113-8. PubMed ID: 20193184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.